外显子组测序与靶向基因组检测用于胎儿积液及非免疫性胎儿水肿产前诊断的成本效益
本研究采用决策分析模型,比较10种基因检测策略在核型或微阵列结果不明确的非免疫性胎儿水肿及胎儿积液病例中的成本效益。外显子组测序在三个孕周区间均成本效益最优,且相比无额外基因检测,靶向基因组检测和外显子组测序均具成本效益。外显子组测序每例检测成本在特定阈值内仍具成本效益。
要点
- 在孕<18周、18–22周及>22周三个区间,外显子组测序单用均为成本最低且质量调整生命年最高的策略。
- 外显子组测序单用或序贯检测较无外显子组测序策略终止妊娠更多,但死产、新生儿死亡及受累婴儿更少。
- 外显子组测序每例检测成本在<18周为50451美元、18–22周为50423美元、>22周为9530美元以内时具成本效益。
核心结论
- 对于核型或微阵列结果不明确的非免疫性胎儿水肿及胎儿积液病例,二代测序相比无额外基因检测策略具成本效益。
- 在采用二代测序时,外显子组测序相比所有靶向基因组检测策略具成本效益,成本更低且不良围产结局更少。
- 在无法选择终止妊娠的情况下,外显子组测序仍具成本效益。
- 作者认为这些数据支持在寻求二代测序以明确不明原因非免疫性胎儿水肿及胎儿积液遗传诊断时常规使用外显子组测序。
研究设计与样本
- 决策分析模型(TreeAge Pro),比较10种基因检测策略:单一检测(RASopathy、代谢或非免疫性胎儿水肿靶向基因组检测或外显子组测序)、序贯检测(RASopathy基因组检测后非免疫性胎儿水肿基因组检测、代谢基因组检测后非免疫性胎儿水肿基因组检测、RASopathy基因组检测后外显子组测序、代谢基因组检测后外显子组测序、非免疫性胎儿水肿基因组检测后外显子组测序)及无额外基因检测。
- 理论队列为核型或微阵列正常且排除同种免疫和先天性病毒感染病例,按孕周分10–18周、18–22周及>22周三个时间区间计算结局。
主要发现
- 外显子组测序单用或序贯检测较无外显子组测序策略终止妊娠更多,但死产、新生儿死亡及受累婴儿更少。
关键数值与推荐
- 成本效益阈值为每质量调整生命年100000美元。
- 外显子组测序具成本效益的每例检测成本上限:孕<18周为50451美元,孕18–22周为50423美元,孕>22周为9530美元。
- 靶向基因组检测和外显子组测序相比无额外基因检测均为具成本效益策略。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although exome sequencing has a greater overall diagnostic yield than targeted gene panels in the evaluation of nonimmune hydrops fetalis and fetal effusions, the cost-effectiveness of this approach is not known. OBJECTIVE: This study aimed to evaluate the costs and outcomes of targeted gene panels vs exome sequencing for prenatally diagnosed nonimmune hydrops fetalis and fetal effusions when next-generation sequencing is pursued following nondiagnostic standard nonimmune hydrops fetalis evaluations, including karyotype or chromosomal microarray. STUDY DESIGN: A decision-analytical model was designed using TreeAge Pro to compare 10 genetic testing strategies, including a single test only (RASopathy, metabolic, or nonimmune hydrops fetalis-targeted gene panel or exome sequencing), sequential testing (RASopathy panel followed by nonimmune hydrops fetalis panel, metabolic panel followed by nonimmune hydrops fetalis panel, RASopathy panel followed by exome sequencing, metabolic panel followed by exome sequencing, and nonimmune hydrops fetalis panel followed by exome sequencing), and no additional genetic testing. Our theoretical cohort included cases with normal karyotype and/or microarray and excluded cases of alloimmunization and congenital viral infections. As nonimmune hydrops fetalis and fetal effusions can present throughout gestation, whereas pregnancy management options vary depending on gestational age, outcomes were calculated for 3 time intervals: 10 to 18, 18 to 22, and >22 weeks of gestation. The primary outcome was incremental cost per quality-adjusted life year. Additional outcomes included termination of pregnancy, stillbirth, neonatal death, and neonates born with mild, moderate, and severe or profound disease phenotypes. The cost-effectiveness threshold was $100,000 per quality-adjusted life year. RESULTS: Among women <18 weeks of gestation, exome sequencing alone was the dominant strategy associated with the lowest costs ($221 million) and the highest quality-adjusted life years (10,288). Strategies with exome sequencing alone or as a sequential test resulted in more terminations but fewer stillbirths, neonatal deaths (NNDs), and affected infants than strategies without exome sequencing. Among women between 18 and 22 weeks of gestation, exome sequencing alone was also associated with the lowest costs ($188 million) and the highest quality-adjusted life years (8734), and similar trends were observed in pregnancy outcomes. Among patients >22 weeks of gestations, when termination was not available, exome sequencing was associated with lower costs ($300 million) and the highest quality-adjusted life years (8492). Exome sequencing was cost-effective up to a cost per test of $50,451 at <18 weeks of gestation, $50,423 at 18 to 22 weeks of gestation, and $9530 at >22 weeks of gestation. Targeted genetic panels and exome sequencing were cost-effective strategies compared with no additional genetic testing. CONCLUSION: For cases of nonimmune hydrops fetalis and fetal effusions with nondiagnostic karyotype or microarray, next-generation sequencing was cost-effective compared with a strategy without additional genetic testing. For those that undergo next-generation sequencing, exome sequencing was the cost-effective strategy compared with all other testing strategies using targeted gene panels, leading to lower costs and fewer adverse perinatal outcomes. Exome sequencing was cost-effective in a setting without the option for pregnancy termination. These data supported the routine use of exome sequencing when next-generation sequencing is pursued for establishing a genetic diagnosis underlying otherwise unexplained nonimmune hydrops fetalis and fetal effusions.
引用
- Avram CM, Caughey AB, Norton ME, et al. Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis. Am J Obstet Gynecol MFM. 2022. PMID: 35995366. doi:10.1016/j.ajogmf.2022.100724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。